Septerna (NASDAQ:SEPN) Issues Quarterly Earnings Results, Misses Expectations By $0.15 EPS

Septerna (NASDAQ:SEPN) released its quarterly earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15), FiscalAI reports. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The firm had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million.

Septerna Trading Up 3.9%

NASDAQ:SEPN traded up $1.89 on Monday, reaching $50.74. 713,677 shares of the stock traded hands, compared to its average volume of 365,581. Septerna has a 1-year low of $17.98 and a 1-year high of $51.10. The company’s 50 day moving average is $39.52 and its 200-day moving average is $32.59. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -93.96 and a beta of 2.20.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SEPN. HC Wainwright boosted their target price on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. raised their price target on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. Guggenheim lifted their price objective on shares of Septerna from $51.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday. Wells Fargo & Company boosted their price objective on shares of Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a report on Wednesday, November 4th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.22.

Insider Activity

In other news, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. The trade was a 12.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Daniel Long sold 3,333 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 32,333 shares of company stock valued at $1,375,727. Corporate insiders own 5.80% of the company’s stock.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.